Grunberger, George
Rosenfeld, Cheryl R.
Bode, Bruce W.
Abbott, Scott D.
Nikkel, Carla http://orcid.org/0000-0002-7206-1094
Shi, Leon
Strange, Poul
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study
https://doi.org/10.1007/s40801-019-00173-8
Funding for this research was provided by:
Valeritas
Article History
First Online: 12 December 2019
Compliance with Ethical Standards
:
: This study was sponsored by Valeritas Inc, Bridgewater, NJ, USA. Statistical interpretation, medical writing, and editorial assistance were funded by the sponsor. Open access fees are funded by the sponsor.
: All investigators’ institutions received financial support from Valeritas, Inc. to conduct the clinical trial. G.G. reports that he is a speaker for BI-Lilly, Lilly, Novo Nordisk, and Sanofi. He has also received research grant support from Medtronic and Novo Nordisk. C.R. reports no competing financial interests. B.B. has received speaker and consultant fees from AstraZeneca, BI-Lilly, Janssen, Medtronic, Novo Nordisk, and Sanofi; his employer (Atlanta Diabetes Association) has received research and grant support from Abbott, Dexcom, and Medtronic. S.A. and C.N. are employees of and stockholders in Valeritas, Inc. P.S. has received consultant fees and is a stockholder in Valeritas.com. L.S. reports no competing financial interests.
: The study protocol was reviewed and approved by the New England Institutional Review Board (NEIRB) before the start of the study, and was registered in the ClinicalTrial.gov registry (identifier: NCT01326598). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.